×

Register now for access to the Parexel Biotech Content Hub

First Name
Last Name
Company Name
Job Title
Country
Thank you!
Error - something went wrong!
   

Challenging Conventional Patient Recruitment And Care Strategies For Rare Disease Studies

August 22, 2017

The number of orphan drug designations doubled between 2007 and 2014; and drugs for rare diseases accounted for 41% of new FDA-approved drugs in 2016. Aided by a variety of supportive FDA policies, orphan drugs have had a higher overall success rate than their counterparts from 2006-2015: 25% of orphan drugs advanced successfully from Phase I to FDA approval versus only 9.6% of nonorphan drugs, spurring investment from companies and giving new hope to patients suffering from heretofore untreatable diseases. Read this article to find out more. 

Previous Flipbook
Better Listening to Increase Site Engagement
Better Listening to Increase Site Engagement

Find out how Parexel uses feedback from clinical site investigator surveys.

No More Flipbooks